Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.83
+8.3%
$1.46
$1.03
$8.64
$57.09M-0.27500,864 shs336,408 shs
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.20
$0.17
$2.96
$13.00M-19.974,200 shsN/A
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
$1.42
+15.4%
$0.96
$0.60
$4.18
$63.72M0.66436,476 shs1.04 million shs
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$1.14
+7.5%
$0.95
$0.69
$7.45
$54.61M1.72357,077 shs123,352 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-1.17%+6.96%+22.46%+48.25%-79.26%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%0.00%0.00%-79.79%
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-6.11%-3.91%+31.97%0.00%-65.74%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-8.62%-1.85%+21.83%-13.82%-85.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
1.8862 of 5 stars
3.42.00.00.03.10.00.6
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/AN/AN/AN/A
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
2.9606 of 5 stars
3.51.00.00.02.55.00.6
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
1.8197 of 5 stars
3.42.00.00.00.01.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2.75
Moderate Buy$4.00118.58% Upside
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00
N/AN/AN/A
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
3.00
Buy$8.33486.85% Upside
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
2.71
Moderate Buy$7.50557.89% Upside

Current Analyst Ratings Breakdown

Latest CHHE, STTK, HOWL, and ATNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
5/9/2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.00
4/28/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
4/1/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
3/27/2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
3/27/2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/25/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
3/18/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
3/17/2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/17/2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$4.00
3/12/2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.00
(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$81K704.80N/AN/A$1.31 per share1.40
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$110K0.00N/A47.17$0.60 per share0.00
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
$1.14M55.75N/AN/A$3.08 per share0.46
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$4.61M11.86N/AN/A$3.41 per share0.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M-$1.39N/AN/AN/AN/A-100.85%-47.89%N/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
-$410K-$0.02N/AN/AN/AN/AN/AN/AN/A
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$37.37M-$1.67N/AN/AN/A-578.80%-58.83%-38.45%8/14/2025 (Estimated)
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$87.30M-$1.39N/AN/AN/A-1,156.46%-61.92%-54.49%7/30/2025 (Estimated)

Latest CHHE, STTK, HOWL, and ATNM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$0.44-$0.40+$0.04-$0.40$0.30 millionN/A
5/1/2025Q1 2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.29-$0.27+$0.02-$0.27N/AN/A
3/27/2025Q4 2024
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.38-$0.37+$0.01-$0.37$1.00 millionN/A
3/11/2025Q4 2024
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$0.43-$0.46-$0.03-$0.46$1.00 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/A
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
N/AN/AN/AN/AN/A
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/A
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
0.29
10.10
10.10
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/A
7.96
7.96

Institutional Ownership

CompanyInstitutional Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/A
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
64.84%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
58.74%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3031.20 million29.32 millionOptionable
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
4064.95 million44.62 millionNot Optionable
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
4044.87 million35.16 millionOptionable
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
10047.90 million42.73 millionOptionable

Recent News About These Companies

Shattuck Labs Full Year 2024 Earnings: Misses Expectations
Shattuck Labs reports Q4 EPS (37c), consensus (32c)
H.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)
Shattuck Labs initiated with an Outperform at Leerink
H.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.83 +0.14 (+8.28%)
Closing price 04:00 PM Eastern
Extended Trading
$1.80 -0.04 (-1.91%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

China Health Industries stock logo

China Health Industries OTCMKTS:CHHE

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.

Werewolf Therapeutics stock logo

Werewolf Therapeutics NASDAQ:HOWL

$1.42 +0.19 (+15.45%)
Closing price 04:00 PM Eastern
Extended Trading
$1.41 -0.01 (-0.70%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Shattuck Labs stock logo

Shattuck Labs NASDAQ:STTK

$1.14 +0.08 (+7.55%)
Closing price 04:00 PM Eastern
Extended Trading
$1.14 0.00 (-0.35%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.